Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
RxSight Community
NasdaqGM:RXST Community
1
Narratives
written by author
0
Comments
on narratives written by author
13
Fair Values set
on narratives written by author
Create a narrative
RxSight
Popular
Undervalued
Overvalued
Community Investing Ideas
RxSight
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
South Korea And UK Approvals Will Expand Market Adoption
Key Takeaways International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support. Innovation pipeline, including new treatments and software updates, is expected to improve outcomes, increase adoption, and drive revenue growth.
View narrative
US$21.18
FV
25.0% undervalued
intrinsic discount
17.54%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
RXST
RXST
RxSight
Your Fair Value
US$
Current Price
US$15.89
25.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-62m
257m
2015
2018
2021
2024
2025
2027
2030
Revenue US$256.9m
Earnings US$36.7m
Advanced
Set Fair Value